Literature DB >> 14757157

Antitussive activity of the tachykinin NK1 receptor antagonist, CP-99994, in dogs.

Richard W Chapman1, Aileen House, Fei Liu, Chander Celly, Hong Mei, John A Hey.   

Abstract

CP-99994 [(+)-(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine] is a selective tachykinin NK(1) receptor antagonist that inhibits cough in guinea pigs and cats. This study examined the antitussive effects of CP-99994 in dogs produced by mechanical stimulation of the intrathoracic trachea. CP-99994 (10 mg/kg, p.o.) inhibited cough frequency by 52% at 2 h, 31% at 6 h and by 21% at 24 h. Cough amplitude was inhibited by 45% at 6 h but unchanged at 2 and 24 h after CP-99994. Plasma levels of CP-99994 were highest at 2 h (75+/-26 ng/ml) and fell to 22+/-6 ng/ml at 6 h. These results demonstrate antitussive activity of CP-99994 in dogs at a dose proven to antagonize tachykinin NK(1) receptors in this species.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14757157     DOI: 10.1016/j.ejphar.2003.11.048

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

Review 1.  Central mechanisms II: pharmacology of brainstem pathways.

Authors:  D C Bolser
Journal:  Handb Exp Pharmacol       Date:  2009

Review 2.  Central regulation of the cough reflex: therapeutic implications.

Authors:  Brendan J Canning
Journal:  Pulm Pharmacol Ther       Date:  2009-01-20       Impact factor: 3.410

3.  Investigation of Neurokinin-1 Receptor Antagonism as a Novel Treatment for Chronic Bronchitis in Dogs.

Authors:  M Grobman; C Reinero
Journal:  J Vet Intern Med       Date:  2016-03-20       Impact factor: 3.333

Review 4.  Peripheral mechanisms II: the pharmacology of peripherally active antitussive drugs.

Authors:  D Spina; I McFadzean; F K R Bertram; C P Page
Journal:  Handb Exp Pharmacol       Date:  2009
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.